Gyre Pharmaceuticals Receives IND Approval From China'S NMPA

Gyre Pharmaceuticals Receives IND Approval From China'S NMPA To Evaluate F230 For The Treatment Of Pulmonary Arterial Hypertension

Gyre Pharmaceuticals Receives IND Approval From China'S NMPA To Evaluate F230 For The Treatment Of Pulmonary Arterial Hypertension

menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.

Related Keywords

United States , China , San Diego , California , Chan Ying , Yunnan , , Exchange Commission , Gyre Through Pharmaceuticals , Group Ltd , China National Medical Products Administration , Gyre Pharmaceuticals , Drug Evaluation , National Medical Products Administration , Gyre Pharmaceutical , Investigational New Drug , Chief Executive Officer , Private Securities Litigation Reform Act , Annual Report ,